Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis

Qing Xue, Xue Q, Zhihong Lin, Lin Z, You-Hong Cheng, Cheng YH, Chiang-Ching Huang, Chiang‐Ching Huang, Huang CC, Marsh E, Erica E. Marsh, Erica Marsh, Yin P, Ping Yin, Magdy P. Milad, Edmond Confino, Confino E, Scott Reierstad, Reierstad S, Joy Innes, Innes J, Serdar E. Bulun, Bulun Se
Biology of reproduction · 2007 · vol. 77(4) , pp. 681–687 · doi:10.1095/biolreprod.107.061804 · PMID:17625110 · W2164434026
Lab / animal OA: closed CC0 ⤵ 240 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This study found that differential methylation of a CpG island in the ESR2 gene promoter region is responsible for the significantly higher ESR2 mRNA levels observed in human endometriotic stromal cells compared to endometrial stromal cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Steroid receptors in the stromal cells of endometrium and its disease counterpart tissue endometriosis play critical physiologic roles. We found that mRNA and protein levels of estrogen receptor 2 (ESR2) were strikingly higher, whereas levels of estrogen receptor 1 (ESR1), total progesterone receptor (PGR), and progesterone receptor B (PGR B) were significantly lower in endometriotic versus endometrial stromal cells. Because ESR2 displayed the most striking levels of differential expression between endometriotic and endometrial cells, and the mechanisms for this difference are unknown, we tested the hypothesis that alteration in DNA methylation is a mechanism responsible for severely increased ESR2 mRNA levels in endometriotic cells. We identified a CpG island occupying the promoter region (-197/+359) of the ESR2 gene. Bisulfite sequencing of this region showed significantly higher methylation in primary endometrial cells (n = 8 subjects) versus endometriotic cells (n = 8 subjects). The demethylating agent 5-aza-2'-deoxycytidine significantly increased ESR2 mRNA levels in endometrial cells. Mechanistically, we employed serial deletion mutants of the ESR2 promoter fused to the luciferase reporter gene and transiently transfected into both endometriotic and endometrial cells. We demonstrated that the critical region (-197/+372) that confers promoter activity also bears the CpG island, and the activity of the ESR2 promoter was strongly inactivated by in vitro methylation. Taken together, methylation of a CpG island at the ESR2 promoter region is a primary mechanism responsible for differential expression of ESR2 in endometriosis and endometrium. These findings may be applied to a number of areas ranging from diagnosis to the treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

DNA Methylation DNA Methylation Endometriosis Endometrium Estrogen Receptor beta Gene Expression Regulation Adult Adult Azacitidine Azacitidine Azacitidine Azacitidine Cells, Cultured Cells, Cultured CpG Islands CpG Islands Decitabine Decitabine Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (43)

Cited by (50)

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:04:31.715410+00:00
License: CC0 · commercial use OK